Bayer Sorafenib/Placebo with mFOLFOX6 in metastatic CRC - version 1

• Research type

  Research Study

• Full title

  A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib Compared with Placebo When Administered in Combination with Chemotherapy (Modified FOLFOX6) for the Treatment of Metastatic Colorectal Cancer in Subjects Who Have Not Been Previously Treated for Stage IV disease.

• Sponsor organisation

  Bayer Healthcare AG

• Eudract number

  2008-005025-11

• Clinicaltrials.gov Identifier

  00865709

• Research summary

  Research Summary not published at request of researcher

• REC name

  West of Scotland REC 1

• REC reference

  09/S0703/40

• Date of REC Opinion

  6 May 2009

• REC opinion

  Further Information Favourable Opinion